Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1976 Aug 17;48(3):295-301.
doi: 10.1007/BF00496865.

Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes

Comparative Study

Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes

P Placheta et al. Psychopharmacology (Berl). .

Abstract

The influence of mepiprazole (EMD 16,923), a new pyrazol-ylalkyl-piperazine derivative, on the uptake of 3H-norepinephrine (NE), 3H-dopamine (DA), and 3H-serotonin (5-HT) into rat brain synaptosomes from cerebral cortex, corpus striatum, and hypothalamus was investigated in comparison with several psychotropic drugs, including oxypertine, d-amphetamine, imipramine, desipramine, chlorimipramine, amitriptyline, and chlorpromazine in vitro. Mepiprazole was a relatively weak inhibitor of monoamine uptake and exhibited its strongest action on the hypothalamic 5-HT uptake, being almost equipotent with desipramine (IC50 = 0.9 MUM). Furthermore, the influence of the drugs on the retention of 3H-amines previously taken up by whole rat brain synaptosomes was studied. Unlike the tricyclic antidepressants, mepiprazole as well as oxypertine and d-amphetamine markedly increased the efflux of radioactivity during a 20-min incubation at 37 degrees C at low concentrations (10(-6) to 10(-5) M), whereas at 10(-4) M all drugs greatly enhanced the efflux. The ability of mepiprazole to increase 5-HT concentration at the receptor level by a combination of neuronal uptake inhibition and release is discussed in relationship to the central actions of the drug.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharm Pharmacol. 1968 Mar;20(3):230-1 - PubMed
    1. Acta Physiol Scand. 1966 Jul-Aug;67(3):481-97 - PubMed
    1. Biochem Pharmacol. 1973 Feb 1;22(3):311-22 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R4 - PubMed
    1. Pharmakopsychiatr Neuropsychopharmakol. 1973 May;6(3):167-77 - PubMed

Publication types

LinkOut - more resources